Celyad Oncology S.A. (CLYYF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Celyad Oncology S.A. (CLYYF) trades at $0.25 with AI Score 61/100 (Grade B+). Celyad Oncology S. A. is a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies for cancer treatment. Market cap: $11.19M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CLYYF: CLYYF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLYYF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CLYYF: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Celyad Oncology S.A. (CLYYF) Healthcare & Pipeline Overview
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm focused on pioneering CAR-T cell therapies, with a robust pipeline targeting various cancers, positioning itself as a key player in the evolving oncology landscape.
What Is the Investment Thesis for CLYYF?
Celyad Oncology S.A. presents a compelling investment thesis driven by its innovative CAR-T cell therapy pipeline. The company's lead candidates, CYAD-101 and CYAD-211, are in advanced clinical trials, with potential market opportunities in colorectal cancer and multiple myeloma, respectively. The global CAR-T cell therapy market is projected to reach $30 billion by 2026, suggesting significant revenue potential for successful product launches. Celyad's unique approach to allogeneic CAR-T therapies differentiates it from competitors, potentially positioning the company for rapid growth. However, investors should remain cautious of the inherent risks in clinical trials, including regulatory approval timelines and competitive pressures from established players in the biotechnology sector.
Based on FMP financials and quantitative analysis
CLYYF Key Highlights
- Market Cap of $11.19M reflects the company's current valuation in the biotechnology sector.
- P/E ratio of 14.6 indicates the company's earnings relative to its share price, suggesting investor confidence.
- Profit margin of 3833.3% showcases the company's potential for profitability in its niche market.
- Gross margin of 9195.2% highlights the high-value nature of its biopharmaceutical products.
- Beta of 1.19 indicates a slightly higher volatility compared to the broader market.
Who Are CLYYF's Competitors?
CLYYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $61.78 | +2.83% | $5.96B | 44 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| ZIOP ZIOPHARM Oncology, Inc. | $0.87 | -0.88% | $208.12M | 49 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLYYF's Key Strengths?
- Innovative pipeline of CAR-T therapies targeting significant cancer indications.
- Strong partnerships with established pharmaceutical companies.
- Experienced leadership team with expertise in biotechnology.
- Robust intellectual property portfolio protecting key technologies.
What Are CLYYF's Weaknesses?
- Limited operational scale with only 17 employees.
- Dependence on clinical trial outcomes for future growth.
- Relatively low market capitalization may limit investor interest.
- Challenges in navigating regulatory approval processes.
What Could Drive CLYYF Stock Higher?
- Results from Phase 1b clinical trial of CYAD-101 for metastatic colorectal cancer expected in Q4 2026.
- Phase 1 clinical trials for CYAD-211 targeting relapsed/refractory multiple myeloma.
- Advancements in preclinical trials for CYAD-203, with potential milestones in 2026.
- Collaborations with Novartis and Horizon Discovery enhancing research capabilities.
- Strategic partnerships aimed at expanding market access and funding for clinical trials.
What Are the Key Risks for CLYYF?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory approval delays for clinical trials could impact product timelines.
- Competition from established biotechnology firms may affect market share.
- Clinical trial outcomes may not meet expectations, leading to reduced investor confidence.
- Market volatility could impact stock performance and investor sentiment.
What Are the Growth Opportunities for CLYYF?
- Growth opportunity 1: Celyad's lead candidate, CYAD-101, is in Phase 1b trials for metastatic colorectal cancer, a market projected to reach $20 billion by 2026. Successful trial outcomes could lead to expedited regulatory approval and market entry, capitalizing on the urgent need for effective therapies in this indication.
- Growth opportunity 2: The Phase 1 clinical trials for CYAD-211 targeting relapsed/refractory multiple myeloma tap into a market expected to grow to $25 billion by 2026. With few effective treatment options available, a successful launch could significantly enhance Celyad's market presence and revenue potential.
- Growth opportunity 3: Celyad's preclinical candidate, CYAD-203, aims to address solid tumors, a growing area of interest in oncology. The solid tumor market is expected to exceed $40 billion by 2026, and Celyad's innovative approach could provide a competitive edge in this lucrative segment.
- Growth opportunity 4: Collaborations with established firms like Novartis and Horizon Discovery enhance Celyad's research capabilities and market access. These partnerships could accelerate the development of its allogeneic CAR-T platforms, driving future growth and innovation.
- Growth opportunity 5: As the global CAR-T therapy market is projected to reach $30 billion by 2026, Celyad's focus on allogeneic therapies positions it to capture a significant share of this expanding market, especially as healthcare providers seek more accessible treatment options.
What Opportunities Does CLYYF Have?
- Expanding CAR-T therapy market with increasing cancer prevalence.
- Potential for successful product launches in underserved indications.
- Collaborative opportunities with research institutions and pharmaceutical companies.
- Growing interest in innovative cancer treatments from investors.
What Threats Does CLYYF Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles and uncertainties in clinical trial outcomes.
- Potential for patent expirations and biosimilar competition.
- Market volatility affecting investor confidence in biotechnology stocks.
What Are CLYYF's Competitive Advantages?
- Innovative focus on allogeneic CAR-T therapies differentiates Celyad from competitors.
- Strong intellectual property portfolio protects proprietary technologies.
- Established partnerships with leading firms enhance research capabilities.
- Experienced leadership team with a track record in biotechnology.
- Robust pipeline of clinical candidates targeting significant market needs.
What Does CLYYF Do?
Founded in 2004 and headquartered in Mont-Saint-Guibert, Belgium, Celyad Oncology S.A. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company was previously known as Celyad SA until it rebranded in June 2020 to reflect its focus on oncology. Celyad's lead product candidates include CYAD-101, currently in a Phase 1b clinical trial for metastatic colorectal cancer, and CYAD-211, an allogeneic CAR-T candidate utilizing short hairpin RNA (shRNA) technology, which is in Phase 1 clinical trials for relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T candidate, is undergoing Phase 1 clinical trials for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company also has a promising preclinical candidate, CYAD-203, designed to co-express interleukin-18 with NKG2D ligands for treating solid tumors. Celyad has established licensing agreements with Novartis International AG concerning patents on allogeneic CAR-T cells and collaborates with Horizon Discovery Group plc to leverage its shRNA technology for developing a second non-gene-edited allogeneic platform. With a small workforce of 17 employees, Celyad Oncology is strategically positioned to advance its innovative therapies in a competitive biotechnology landscape.
What Products and Services Does CLYYF Offer?
- Develops CAR-T cell therapies for cancer treatment.
- Conducts clinical trials for innovative oncology therapies.
- Collaborates with leading pharmaceutical companies for research and development.
- Focuses on allogeneic CAR-T candidates to improve accessibility.
- Engages in preclinical research for novel cancer therapies.
- Holds patents and licensing agreements to protect its innovations.
How Does CLYYF Make Money?
- Generates revenue through licensing agreements with pharmaceutical companies.
- Secures funding through partnerships and collaborations for research and development.
- Aims to commercialize successful therapies post-regulatory approval.
- Utilizes clinical trial data to attract investment and partnerships.
- Explores grants and public funding for innovative research projects.
What Industry Does CLYYF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genetic therapies and personalized medicine. The CAR-T cell therapy segment, in particular, is gaining traction, with the market expected to expand significantly due to increasing cancer prevalence and the demand for effective treatment options. Celyad Oncology S.A. operates in this dynamic landscape, competing with established players and emerging companies focused on innovative cancer therapies. The competitive landscape includes a variety of firms developing both autologous and allogeneic CAR-T therapies, with Celyad's unique focus on allogeneic options setting it apart.
Who Are CLYYF's Key Customers?
- Pharmaceutical companies seeking innovative cancer therapies.
- Healthcare providers looking for advanced treatment options.
- Patients with unmet medical needs in oncology.
- Investors interested in biotechnology and healthcare innovations.
- Research institutions collaborating on clinical studies.
Celyad Oncology S.A. (CLYYF) Valuation Context
Valued at $11.19M, CLYYF is classified as a micro-cap stock. Relative to its peer group, CLYYF's quantitative score of 61/100 is roughly in line with the peer average of 63/100.
CLYYF Revenue & Earnings Trend
In Q4 2025, CLYYF generated $7K in top-line revenue, marking a sequential decrease of 50.0%. The company recorded net income of $4.5M, with diluted EPS of $0.11. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CLYYF averaged $-0.04 in diluted EPS.
Company Profile
Celyad Oncology S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mont-Saint-Guibert, BE. The company is led by CEO Michel E. J. Lussier. CLYYF has traded publicly since 2014.
P/E 14.6Key Financial Metrics
Return on assets is 18.7%, showing how much profit it generates from its asset base. CLYYF trades at a trailing price-to-earnings ratio of 14.62, below the Healthcare sector average of ~23x. Its free cash flow yield is -61.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Celyad Oncology S.A.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CLYYF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Celyad's future, indicating that key stakeholders believe in the company's potential.
- The community sentiment has shifted positively, with increased discussions around Celyad's innovative therapies and their potential impact on cancer treatment.
- Recent clinical trial updates have generated excitement, as investors see promising results that could enhance Celyad's market position.
- Collaborations with leading research institutions have bolstered credibility, enhancing Celyad's visibility in the oncology sector.
Bear Case
- Concerns about funding and cash flow have surfaced, creating uncertainty about the company's ability to sustain operations long-term.
- Community sentiment has been mixed, with some investors expressing skepticism about the scalability of Celyad's therapies in a competitive market.
- Recent regulatory challenges have raised red flags, making investors wary of potential delays in product development and market entry.
- The volatility in biotech stocks has led to heightened caution among traders, impacting overall confidence in Celyad's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $6,997 | $5M | $0.11 |
| Q2 2025 | $14,000 | -$4M | -$0.09 |
| Q4 2024 | $172,000 | -$3M | -$0.07 |
| Q2 2024 | $14,000 | -$3M | -$0.12 |
Based on FMP financials and quantitative analysis
CLYYF Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 10, 2019
CLYYF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLYYF.
Price Targets
Wall Street price target analysis for CLYYF.
CLYYF MoonshotScore
What does this score mean?
The MoonshotScore rates CLYYF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michel E. J. Lussier
CEO
Michel E. J. Lussier has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He has a strong track record in strategic planning and operational management, contributing to the growth of innovative therapies. Lussier holds a degree in life sciences and has been instrumental in advancing Celyad's mission to develop cutting-edge cancer treatments.
Track Record: Under Lussier's leadership, Celyad has successfully advanced multiple product candidates into clinical trials, established key partnerships, and rebranded the company to focus on oncology. His strategic vision has positioned Celyad as a notable player in the biotechnology landscape.
CLYYF OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the higher listing standards of major exchanges like NYSE or NASDAQ. This tier often includes smaller companies with less liquidity and visibility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited visibility and analyst coverage compared to larger exchanges.
- Higher volatility and potential for significant price swings.
- Regulatory scrutiny may differ from that of major exchanges.
- Potential for lower investor confidence due to limited financial disclosures.
- Verify the company's financial health through available reports.
- Assess the progress of clinical trials and product pipelines.
- Evaluate the strength of partnerships and collaborations.
- Review the competitive landscape and market positioning.
- Monitor regulatory developments affecting the biotechnology sector.
- Established partnerships with reputable pharmaceutical companies.
- Presence of experienced leadership with a strong track record.
- Active engagement in clinical trials and research initiatives.
- Patents and intellectual property portfolio indicating innovation.
What Investors Ask About Celyad Oncology S.A. (CLYYF) — Healthcare
What does Celyad Oncology S.A. do?
Celyad Oncology S.A. is a clinical-stage biopharmaceutical company focused on developing CAR-T cell therapies for cancer treatment. The company’s lead candidates include CYAD-101 for metastatic colorectal cancer, CYAD-211 for relapsed/refractory multiple myeloma, and CYAD-02 for acute myeloid leukemia. Celyad aims to address significant unmet medical needs through innovative allogeneic CAR-T therapies.
How does Celyad Oncology S.A. navigate regulatory approval processes?
Celyad Oncology S.A. follows a structured approach to navigate regulatory approval processes, engaging with regulatory agencies such as the FDA and EMA throughout its clinical trial phases. The company ensures compliance with all necessary guidelines and maintains transparency in reporting trial results. By leveraging its partnerships with established firms, Celyad also benefits from shared expertise in regulatory matters, which can expedite the approval process for its innovative therapies.
What are the main risks for CLYYF?
Celyad Oncology S.A. faces several risks, including potential delays in regulatory approvals for its clinical trials, which could impact product launch timelines. Additionally, the company operates in a highly competitive biotechnology landscape, where established players may overshadow its market presence. Clinical trial outcomes are uncertain, and unfavorable results could lead to decreased investor confidence. Lastly, market volatility can significantly affect the stock's performance, presenting further risks for investors.
What are the key factors to evaluate for CLYYF?
Celyad Oncology S.A. (CLYYF) holds an AI score of 61/100 (moderate). P/E: 14.6x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CLYYF data refresh on this page?
CLYYF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CLYYF's recent stock price performance?
Celyad Oncology S.A. (CLYYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline of CAR-T therapies targeting significant cancer indications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLYYF overvalued or undervalued right now?
Celyad Oncology S.A. (CLYYF) trades at 14.6x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CLYYF?
Before investing in Celyad Oncology S.A. (CLYYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available reports and may be subject to change as new information becomes available.